Vaneeta Verma, Ph.D.
Affiliations: | 2011 | Pharmacology | University of Toronto, Toronto, ON, Canada |
Area:
PharmacologyGoogle:
"Vaneeta Verma"Mean distance: 35622
Parents
Sign in to add mentor| Susan R. George | grad student | 2011 | University of Toronto | |
| (Regulation of the Dopamine D1-D2 Receptor Heterooligomer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kong MM, Verma V, O'Dowd BF, et al. (2011) The role of palmitoylation in directing dopamine D1 receptor internalization through selective endocytic routes. Biochemical and Biophysical Research Communications. 405: 445-9 |
| Verma V, Hasbi A, O'Dowd BF, et al. (2010) Dopamine D1-D2 receptor Heteromer-mediated calcium release is desensitized by D1 receptor occupancy with or without signal activation: dual functional regulation by G protein-coupled receptor kinase 2. The Journal of Biological Chemistry. 285: 35092-103 |
| Mann A, Verma V, Basu D, et al. (2010) Specific binding of photoaffinity-labeling peptidomimetics of Pro-Leu-Gly-NH2 to the dopamine D2L receptor: evidence for the allosteric modulation of the dopamine receptor. European Journal of Pharmacology. 641: 96-101 |
| So CH, Verma V, Alijaniaram M, et al. (2009) Calcium signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers. Molecular Pharmacology. 75: 843-54 |
| Rashid AJ, O'Dowd BF, Verma V, et al. (2007) Neuronal Gq/11-coupled dopamine receptors: an uncharted role for dopamine. Trends in Pharmacological Sciences. 28: 551-5 |
| So CH, Verma V, O'Dowd BF, et al. (2007) Desensitization of the dopamine D1 and D2 receptor hetero-oligomer mediated calcium signal by agonist occupancy of either receptor. Molecular Pharmacology. 72: 450-62 |
| Verma V, Mann A, Costain W, et al. (2005) Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog. The Journal of Pharmacology and Experimental Therapeutics. 315: 1228-36 |